AIM — AIM ImmunoTech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: New York Stock Exchange American
- Employees: 21
- Website: https://aimimmuno.com
Latest SEC filings for AIM
- ARS — 2026-09-30
- S-8 — 2026-07-09
- EFFECT — 2026-06-24
- S-1 — 2026-06-18
- EFFECT — 2026-06-17
- 424B5 — 2026-06-10
- S-1 — 2026-06-08
- 8-K — 2026-06-04
- 424B5 — 2026-05-21
- 8-K — 2026-05-21
Latest AIM news
- — AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays (globenewswire.com)
- — AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential (globenewswire.com)
- — AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data (globenewswire.com)
- — Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers pace (proactiveinvestors.com)
- — AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video (globenewswire.com)
- — Ondine Biomedical pauses trading to raise fresh investment after positive phase III result (proactiveinvestors.com)
- — 1947 Oil & Gas starts AIM trading after £50m fundraising and Gulf acquisition (proactiveinvestors.com)
- — 1947 Oil & Gas makes AIM debut with ambitions to grow production sharply in coming years (proactiveinvestors.com)
Educational tool only — not investment advice.